Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Authors :: Krug, U
Krug, U
Ravandi, F
Ritchie, EK
Sayar, H
Lancet, JE
Craig, MD
Vey, N
Strickland, SA
Schiller, GJ
Jabbour, E
Erba, HP
Pigneux, A
Horst, H-A
Recher, C
Klimek, VM
Cortes, J
Roboz, GJ
Craig, AR
Fox, JA
Ward, R
Smith, JA
Acton, G
Mehta, C
Kantarjian, HM
Stuart, RK
Krug, U
Krug, U
Ravandi, F
Ritchie, EK
Sayar, H
Lancet, JE
Craig, MD
Vey, N
Strickland, SA
Schiller, GJ
Jabbour, E
Erba, HP
Pigneux, A
Horst, H-A
Recher, C
Klimek, VM
Cortes, J
Roboz, GJ
Craig, AR
Fox, JA
Ward, R
Smith, JA
Acton, G
Mehta, C
Kantarjian, HM
Stuart, RK
Source :: Oncology Research and Treatment; vol 38, 121-121; 2296-5270
Publication Year :: 2015

Tools